Navigation path

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  Gambia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  Gambia
  Georgia


   Infocentre

Published: 13 January 2017  
Related theme(s) and subtheme(s)
Frontier research (ERC)
Health & life sciencesGenetic engineering  |  Genomics
Pure sciencesBiology
Success storiesHealth & life sciences
Countries involved in the project described in the article
Spain
Add to PDF "basket"

Killer bug could deliver medicines

A bacterium that causes pneumonia is being redesigned to act as a 'cell doctor' that detects and treats disease from inside the human body.

Photo of a researcher observing cells in petri dish
© kasto - fotolia

(The story was first published in Horizon Magazine)

The idea of using bugs as tiny drug couriers is not new: scientists have been engineering viruses to deliver medicines and fix genetic defects for some time.

However, the potential of viruses is limited because they have a small number of genes and because they do not have an active metabolism of their own and cannot respond to the environment or the host. This limits the scope for their engineering for certain medical purposes.

‘Viruses can only carry a limited amount of information,’ said Professor Luis Serrano at the Centre for Genomic Regulation in Barcelona, Spain. ‘They have genes but, unlike bacteria, they do not have a metabolism so they cannot respond to changes in a human cell.’

Using bacteria instead of viruses to deliver treatments to specific parts of the body would provide greater scope for fighting disease because they have more genes to tweak.

However, bacteria are also significantly more complex to work with. For a start, they typically have cell walls – making it difficult for them to communicate with target cells – and they often draw a strong immune response when implanted into humans.

Now, scientists believe they may have found a suitable candidate that has more genes than a virus but is capable of getting into cells to carry out medical missions – and it’s one that we’ve previously associated with disease.

Pneumonia

Mycoplasma pneumoniae can cause bacterial pneumonia in humans, but also ticks many of the boxes required to become a cell doctor. ‘It has no cell wall, it does not cause major inflammation and it can be grown in the lab,’ explained Prof. Serrano, who studied the bug as part of the CELLDOCTOR project, funded by the EU's European Research Council (ERC).

M. pneumoniae is also a very small bacterium. It is roughly the size of a mitochondrion – the subcellular powerhouse that provides our cells with energy.

Because it is so small and can enter cells without triggering a major immune reaction, Prof. Serrano sees the bug’s potential as a medical tool.

‘We want to engineer a vehicle that can get into the human organism, detect anomalies and repair them,’ he said. ‘It could live inside human cells like a parasite capable of improving health.’

Once inside the target cell, the bacterium would blend in with the other structures already there. But unlike the cell’s other subcellular furniture, the engineered M. pneumoniae bacterium would produce and secrete drugs that a patient needs, or proteins capable of correcting a genetic disease.

It would not cause disease itself because the researchers have genetically engineered the pneumoniae bacterium to ensure that it is not infectious.

Through the CELLDOCTOR project, Prof. Serrano focused on understanding what makes the bacterium tick before exploring its capacity for delivering drugs, vaccines and genes.

By understanding its genetics and biochemistry, the Barcelona-based researchers developed a deeper understanding of the bug – so that they could redesign a simple organism that would act like a living pill.

Thanks to additional ERC funding, Prof. Serrano was able to take this work one step further and look at specific uses of M. pneumoniae for treating lung and genital tract diseases in a project called MICO PLUNG.

‘Our initial work was pointing towards medical applications for M. pneumoniae and this… project was a chance to direct our efforts towards more clinically applied research,’ he explained.

Respiratory disorders

The bacterium is known to live in lung tissue, so researchers are working on how genetically engineered versions of the bug could deliver therapeutic proteins that could fight against infectious respiratory disorders.

The team also see potential for bacteria to be used as vaccines, deliberately training the immune system to fight unwelcome viruses and bacteria.

Research in this area may change the way we think about bacteria such as M. pneumoniae by turning an old foe into a valuable ally.

Project details

  • Project acronym:CellDoctor
  • Participants:Spain (Coordinator)
  • Project Reference N° 232913
  • Total cost: € 2 400 000
  • EU contribution: € 2 400 000
  • Duration:March 2009 - February 2015

  • Project acronym:Mico pLung
  • Participants:Spain (Coordinator)
  • Project Reference N° 335010
  • Total cost: € 165 429
  • EU contribution: € 150 000
  • Duration:July 2013 - December 2014

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

CellDoctor web site

CellDoctor project details

Mico pLung web site

Mico pLung project details

Contacts
Unit A1 - External & internal communication,
Directorate-General for Research & Innovation,
European Commission
Tel : +32 2 298 45 40
  Top   Research Information Center
 
Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  Gambia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  Gambia
  Georgia